Concepts and practices used to develop functional PLGA-based nanoparticulate systems

Hongkee Sah, Laura Thoma, Hari R. Desu, Edel Sah, George C. Wood

Research output: Contribution to journalReview article

111 Citations (Scopus)

Abstract

The functionality of bare polylactide-co-glycolide (PLGA) nanoparticles is limited to drug depot or drug solubilization in their hard cores. They have inherent weaknesses as a drug-delivery system. For instance, when administered intravenously, the nanoparticles undergo rapid clearance from systemic circulation before reaching the site of action. Furthermore, plain PLGA nanoparticles cannot distinguish between different cell types. Recent research shows that surface functionalization of nanoparticles and development of new nanoparticulate dosage forms help overcome these delivery challenges and improve in vivo performance. Immense research efforts have propelled the development of diverse functional PLGA-based nanoparticulate delivery systems. Representative examples include PEGylated micelles/nanoparticles (PEG, polyethylene glycol), polyplexes, polymersomes, core-shell-type lipid-PLGA hybrids, cell-PLGA hybrids, receptor-specific ligand-PLGA conjugates, and theranostics. Each PLGA-based nanoparticulate dosage form has specific features that distinguish it from other nanoparticulate systems. This review focuses on fundamental concepts and practices that are used in the development of various functional nanoparticulate dosage forms. We describe how the attributes of these functional nanoparticulate forms might contribute to achievement of desired therapeutic effects that are not attainable using conventional therapies. Functional PLGA-based nanoparticulate systems are expected to deliver chemotherapeutic, diagnostic, and imaging agents in a highly selective and effective manner.

Original languageEnglish (US)
Pages (from-to)747-765
Number of pages19
JournalInternational journal of nanomedicine
Volume8
DOIs
StatePublished - Feb 21 2013

Fingerprint

Nanoparticles
Dosage Forms
Micelles
Lipids
Polyethylene glycols
Ligands
polylactic acid-polyglycolic acid copolymer
Hybrid Cells
Therapeutic Uses
Diagnostic Imaging
Drug Delivery Systems
Imaging techniques
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Drug Discovery
  • Organic Chemistry

Cite this

Concepts and practices used to develop functional PLGA-based nanoparticulate systems. / Sah, Hongkee; Thoma, Laura; Desu, Hari R.; Sah, Edel; Wood, George C.

In: International journal of nanomedicine, Vol. 8, 21.02.2013, p. 747-765.

Research output: Contribution to journalReview article

Sah, Hongkee ; Thoma, Laura ; Desu, Hari R. ; Sah, Edel ; Wood, George C. / Concepts and practices used to develop functional PLGA-based nanoparticulate systems. In: International journal of nanomedicine. 2013 ; Vol. 8. pp. 747-765.
@article{7307aa77994f450fa788bcdcb7717ddb,
title = "Concepts and practices used to develop functional PLGA-based nanoparticulate systems",
abstract = "The functionality of bare polylactide-co-glycolide (PLGA) nanoparticles is limited to drug depot or drug solubilization in their hard cores. They have inherent weaknesses as a drug-delivery system. For instance, when administered intravenously, the nanoparticles undergo rapid clearance from systemic circulation before reaching the site of action. Furthermore, plain PLGA nanoparticles cannot distinguish between different cell types. Recent research shows that surface functionalization of nanoparticles and development of new nanoparticulate dosage forms help overcome these delivery challenges and improve in vivo performance. Immense research efforts have propelled the development of diverse functional PLGA-based nanoparticulate delivery systems. Representative examples include PEGylated micelles/nanoparticles (PEG, polyethylene glycol), polyplexes, polymersomes, core-shell-type lipid-PLGA hybrids, cell-PLGA hybrids, receptor-specific ligand-PLGA conjugates, and theranostics. Each PLGA-based nanoparticulate dosage form has specific features that distinguish it from other nanoparticulate systems. This review focuses on fundamental concepts and practices that are used in the development of various functional nanoparticulate dosage forms. We describe how the attributes of these functional nanoparticulate forms might contribute to achievement of desired therapeutic effects that are not attainable using conventional therapies. Functional PLGA-based nanoparticulate systems are expected to deliver chemotherapeutic, diagnostic, and imaging agents in a highly selective and effective manner.",
author = "Hongkee Sah and Laura Thoma and Desu, {Hari R.} and Edel Sah and Wood, {George C.}",
year = "2013",
month = "2",
day = "21",
doi = "10.2147/IJN.S40579",
language = "English (US)",
volume = "8",
pages = "747--765",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Concepts and practices used to develop functional PLGA-based nanoparticulate systems

AU - Sah, Hongkee

AU - Thoma, Laura

AU - Desu, Hari R.

AU - Sah, Edel

AU - Wood, George C.

PY - 2013/2/21

Y1 - 2013/2/21

N2 - The functionality of bare polylactide-co-glycolide (PLGA) nanoparticles is limited to drug depot or drug solubilization in their hard cores. They have inherent weaknesses as a drug-delivery system. For instance, when administered intravenously, the nanoparticles undergo rapid clearance from systemic circulation before reaching the site of action. Furthermore, plain PLGA nanoparticles cannot distinguish between different cell types. Recent research shows that surface functionalization of nanoparticles and development of new nanoparticulate dosage forms help overcome these delivery challenges and improve in vivo performance. Immense research efforts have propelled the development of diverse functional PLGA-based nanoparticulate delivery systems. Representative examples include PEGylated micelles/nanoparticles (PEG, polyethylene glycol), polyplexes, polymersomes, core-shell-type lipid-PLGA hybrids, cell-PLGA hybrids, receptor-specific ligand-PLGA conjugates, and theranostics. Each PLGA-based nanoparticulate dosage form has specific features that distinguish it from other nanoparticulate systems. This review focuses on fundamental concepts and practices that are used in the development of various functional nanoparticulate dosage forms. We describe how the attributes of these functional nanoparticulate forms might contribute to achievement of desired therapeutic effects that are not attainable using conventional therapies. Functional PLGA-based nanoparticulate systems are expected to deliver chemotherapeutic, diagnostic, and imaging agents in a highly selective and effective manner.

AB - The functionality of bare polylactide-co-glycolide (PLGA) nanoparticles is limited to drug depot or drug solubilization in their hard cores. They have inherent weaknesses as a drug-delivery system. For instance, when administered intravenously, the nanoparticles undergo rapid clearance from systemic circulation before reaching the site of action. Furthermore, plain PLGA nanoparticles cannot distinguish between different cell types. Recent research shows that surface functionalization of nanoparticles and development of new nanoparticulate dosage forms help overcome these delivery challenges and improve in vivo performance. Immense research efforts have propelled the development of diverse functional PLGA-based nanoparticulate delivery systems. Representative examples include PEGylated micelles/nanoparticles (PEG, polyethylene glycol), polyplexes, polymersomes, core-shell-type lipid-PLGA hybrids, cell-PLGA hybrids, receptor-specific ligand-PLGA conjugates, and theranostics. Each PLGA-based nanoparticulate dosage form has specific features that distinguish it from other nanoparticulate systems. This review focuses on fundamental concepts and practices that are used in the development of various functional nanoparticulate dosage forms. We describe how the attributes of these functional nanoparticulate forms might contribute to achievement of desired therapeutic effects that are not attainable using conventional therapies. Functional PLGA-based nanoparticulate systems are expected to deliver chemotherapeutic, diagnostic, and imaging agents in a highly selective and effective manner.

UR - http://www.scopus.com/inward/record.url?scp=84874357219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874357219&partnerID=8YFLogxK

U2 - 10.2147/IJN.S40579

DO - 10.2147/IJN.S40579

M3 - Review article

C2 - 23459088

AN - SCOPUS:84874357219

VL - 8

SP - 747

EP - 765

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -